Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Crook, Derrick W., Walker, A. Sarah, Kean, Yin, Weiss, Karl, Cornely, Oliver A., Miller, Mark A., Esposito, Roberto, Louie, Thomas J., Stoesser, Nicole E., Young, Bernadette C., Angus, Brian J., Gorbach, Sherwood L., Peto, Timothy E. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388031/
https://www.ncbi.nlm.nih.gov/pubmed/22752871
http://dx.doi.org/10.1093/cid/cis499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388031/
https://www.ncbi.nlm.nih.gov/pubmed/22752871
http://dx.doi.org/10.1093/cid/cis499

Ejemplares similares